Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160

B. Szende, E. Juhasz, K. Lapis, A. V. Schally

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Fisher 344 female rats were exposed for 4 weeks to the initiator carcinogen N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) 0.05% in the drinking water and thereafter to the promoter carcinogen mitomycin C (0.08 mg per animal per week) intravesically for 12 weeks. High incidence of urinary bladder transitional cell cancers was observed (17 in situ and 17 invasive carcinomas among 40 rats). When the somatostatin analogue RC-160 (d-Phe-Cys-Tyr-d-Trp-Lys-Val-Cys-Trp-NH2) was administered s.c. at the dose of 50 μg per animal per day during 6-week period of promotion with mitomycin C, the incidence of urinary bladder cancer was dramatically reduced. Only 1 in situ carcinoma was observed among 20 rats and only preblastomatous lesions (dysplasias and papillomas) occurred. This effect could indicate that RC-160 interferes with the process of promotion by induction of enhanced apoptosis (programmed cell death) of the dysplastic urothelial cells. RC-160 could be tried therapeutically for the hormonal prevention of malignant transformation of preneoplastic lesions in the urinary bladder.

Original languageEnglish (US)
Pages (from-to)383-386
Number of pages4
JournalUrological Research
Issue number6
StatePublished - Oct 1 1992
Externally publishedYes


  • Carcinogenesis
  • Somatostatin analogue
  • Urinary bladder

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160'. Together they form a unique fingerprint.

Cite this